You are here

Cabozantinib (Conetriq) Fails Pivotal Study in Men With Metastatic Castration-Resistant Prostate Cancer

Treatment indicated for medullary thyroid cancer

Disappointing results have been reported from the final analysis of COMET-2, a phase III, randomized, double-blind, controlled trial of cabozantinib (Conetriq, Exelixis, Inc.) in men with metastatic castration-resistant prostate cancer (mCRPC) who were experiencing moderate-to-severe pain despite optimized narcotic medication, and whose disease had progressed after treatment with docetaxel as well as abiraterone and/or enzalutamide.

The trial did not meet its primary endpoint of alleviation of bone pain, as determined by comparing the percentage of patients in the two treatment arms who achieved a pain response at week 6 that was confirmed at week 12 without an increase in narcotic medication.

Fifteen percent of patients in the cabozantinib arm reported a pain response compared with 17% of patients in the control arm (mitoxantrone/prednisone). The difference in pain responses between the two treatment arms was not statistically significant.

In the COMET-2 study, 119 patients were randomly assigned to receive either cabozantinib or mitoxantrone/prednisone. In addition to the primary endpoint of alleviation of bone pain, secondary endpoints included the bone-scan response and overall survival.

Cabozantinib inhibits the activity of tyrosine kinases, including MET, RET, and vascular endothelial growth-factor receptors (VEGFRs). These receptor tyrosine kinases are involved in both normal cellular function and pathologic processes, such as oncogenesis, metastasis, tumor angiogenesis, and maintenance of the tumor microenvironment.

Cometriq (cabozantinib) is approved by the FDA for the treatment of progressive, metastatic medullary thyroid cancer.

Source: Exelixis, Inc.; December 1, 2014.

More Headlines

First and Only Treatment Reduces Depressive Symptoms Within Days
Bone Marrow Cleared of Leukemia in Almost 60% of Patients
Combination of Two Drugs Could Reduce Tumor Growth
Atezolizumab in Combination with Chemotherapy is the Only First-line Cancer Immunotherapy for ES-SCLC
Pre-clinical Trials Showed Drug Inhibits Fibroblast Activity and Collagen Deposition
PARG Inhibitor Exploits Weakness, Kills Cells
Inexpensive, Wearable Therapy Increases Arm Mobility, Reduces Stiffness
National Statistics Report Factors In Race, Ethnicity for the First Time